SUSAN E. KNIGHT - 28 Feb 2022 Form 4 Insider Report for SURMODICS INC (SRDX)

Role
Director
Signature
/s/ John Manders, on behalf of Susan E. Knight
Issuer symbol
SRDX
Transactions as of
28 Feb 2022
Net transactions value
-$108,226
Form type
4
Filing time
02 Mar 2022, 15:02:18 UTC
Previous filing
14 Feb 2022
Next filing
13 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRDX Common Stock Options Exercise $88,106 +4,366 +14% $20.18 34,562 28 Feb 2022 Direct
transaction SRDX Common Stock Sale $196,332 -4,366 -13% $44.97 30,196 28 Feb 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRDX Stock Option (right to buy) Options Exercise $0 -4,366 -100% $0.000000* 0 28 Feb 2022 Common Stock 4,366 $20.18 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the weighted average price of 4,366 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on February 28, 2022 with sale prices ranging from $44.96 to $45.08 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F2 The amount beneficially owned includes 13,203 restricted stock units (RSUs) that vest on service-based vesting dates that will be settled in shares of the issuer's common stock on a 1 for 1 basis when the reporting person's service as a director ends.
F3 Fully vested.